Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>SVN-001 clinical case strengthened. Solvonis has reported two new secondary analyses of the Phase 2 KARE trial of SVN-001, its ketamine-assisted therapy for severe AUD.</li><li>KARE enrolled 96 patients across four arms, with three weekly IV infusions and six months of follow-up.</li><li>The new analysis demonstrated that SVN-001 patients had 67% fewer heavy drinking days (HDD) than placebo at weeks 17 to 20 (p=0.018) with benefits persisting more than four months after treatment. </li></ul>

SVN-001 clinical case strengthened. Solvonis has reported two new secondary analyses of the Phase 2 KARE trial of SVN-001, its ketamine-assisted therapy for severe AUD.KARE enrolled 96 patients across four arms, with three weekly IV infusions and six months of follow-up.The new analysis demonstrated that SVN-001 patients had 67% fewer heavy drinking days (HDD) than placebo at weeks 17 to 20 (p=0.018) with benefits persisting more than four months after treatment. 

SVNS: New Data Sharpens SVN-001's Path to European Expansion

<ul><li>SVN-015 has cleared its first external screening hurdle under NIDA’s Addiction Treatment Discovery Program. </li><li>Solvonis announced that its second AI-driven discovery platform compound, SVN-015, has come through the US National Institute on Drug Abuse (NIDA) initial heart safety and off-target screening and that the NIDA has agreed to take it into the next stage of work.</li><li>That stage should cover confirmatory studies of how SVN-015 binds to and acts on the dopamine transporter, a closer look at its activity at the 5-HT2B receptor, and a mouse study measuring how quickly its effects start and how long they last. </li></ul>

SVN-015 has cleared its first external screening hurdle under NIDA’s Addiction Treatment Discovery Program. Solvonis announced that its second AI-driven discovery platform compound, SVN-015, has come through the US National Institute on Drug Abuse (NIDA) initial heart safety and off-target screening and that the NIDA has agreed to take it into the next stage of work.That stage should cover confirmatory studies of how SVN-015 binds to and acts on the dopamine transporter, a closer look at its activity at the 5-HT2B receptor, and a mouse study measuring how quickly its effects start and how long they last. 

SVNS: SVN-015 Clears First NIDA Hurdle; Adds Validation and Optionality to Solvonis' CNS Pipeline

<ul><li>A differentiated “acute intervention” thesis. Solvonis is developing acute, durable interventions for high-burden central nervous system (CNS) disorders rather than chronic maintenance therapies.</li><li>Its clinical-stage programs are anchored by ketamine’s glutamatergic, an N-methyl-D-aspartate (NMDA) receptor antagonist mechanism, which is thought to induce a transient period of enhanced neuroplasticity during which structured psychotherapy could help remodel the neural circuits underlying craving and addictive behavior.</li><li>The company’s lead indication is alcohol use disorder (AUD), one of the most prevalent substance use disorders in the US and Europe, associated with an annual economic burden estimated in the hundreds of billions of dollars and served by pharmacological treatment options that have seen little innovation in decades. </li></ul>

A differentiated “acute intervention” thesis. Solvonis is developing acute, durable interventions for high-burden central nervous system (CNS) disorders rather than chronic maintenance therapies.Its clinical-stage programs are anchored by ketamine’s glutamatergic, an N-methyl-D-aspartate (NMDA) receptor antagonist mechanism, which is thought to induce a transient period of enhanced neuroplasticity during which structured psychotherapy could help remodel the neural circuits underlying craving and addictive behavior.The company’s lead indication is alcohol use disorder (AUD), one of the most prevalent substance use disorders in the US and Europe, associated with an annual economic burden estimated in the hundreds of billions of dollars and served by pharmacological treatment options that have seen little innovation in decades. 

SVNS: Pursuing Acute Intervention Rather Than Chronic Treatment of High-Burden CNS Conditions

<div><ul><li>Meet Professor David Nutt. David Nutt, the Edmund J. Safra Professor of Neuropsychopharmacology and Director of the Centre for Psychedelic Research at Imperial College London, is a leading authority in the field, with more than 500 scientific publications, 36 books, and eight government reports covering psychedelic science and addiction.</li><li>In summer 2025, he assumed the role of Chief Scientific Officer at Solvonis Therapeutics (having previously served as a senior scientific advisor to the company) through an exclusive collaboration driven by two key pipeline opportunities. </li><li>The first advancing ketamine as a major alternative to existing addiction treatments and the second developing legal MDMA substitutes, currently in safety testing, aimed at becoming the next-generation standard of care for PTSD.</li></ul></div>

Meet Professor David Nutt. David Nutt, the Edmund J. Safra Professor of Neuropsychopharmacology and Director of the Centre for Psychedelic Research at Imperial College London, is a leading authority in the field, with more than 500 scientific publications, 36 books, and eight government reports covering psychedelic science and addiction.In summer 2025, he assumed the role of Chief Scientific Officer at Solvonis Therapeutics (having previously served as a senior scientific advisor to the company) through an exclusive collaboration driven by two key pipeline opportunities. The first advancing ketamine as a major alternative to existing addiction treatments and the second developing legal MDMA substitutes, currently in safety testing, aimed at becoming the next-generation standard of care for PTSD.

Solvonis' Approach to Resetting the Addicted Brain

<ul><li>Strategic pivot to retain SVN-001 value. Solvonis has shifted from pursuing an earlier-stage out-licensing strategy for its lead development asset for alcohol use disorder (AUD) toward advancing SVN-001 through Phase 3 internally.</li><li>Tennyson cited improved investor and regulatory sentiment toward psychedelic-adjacent CNS therapies in the US and the proximity to a major Phase 3 data readout as key factors underscoring the management’s belief that significantly more value will be available to Solvonis shareholders at the end of the Phase 3 by keeping it in-house. </li><li>He also reminded us of the exceptional Phase 2 study data, which showed abstinence rising from 2% pre-treatment to 86% in the six months post-treatment on the active arm, plus a statistically significant reduction in heavy drinking days versus placebo.</li></ul>

Strategic pivot to retain SVN-001 value. Solvonis has shifted from pursuing an earlier-stage out-licensing strategy for its lead development asset for alcohol use disorder (AUD) toward advancing SVN-001 through Phase 3 internally.Tennyson cited improved investor and regulatory sentiment toward psychedelic-adjacent CNS therapies in the US and the proximity to a major Phase 3 data readout as key factors underscoring the management’s belief that significantly more value will be available to Solvonis shareholders at the end of the Phase 3 by keeping it in-house. He also reminded us of the exceptional Phase 2 study data, which showed abstinence rising from 2% pre-treatment to 86% in the six months post-treatment on the active arm, plus a statistically significant reduction in heavy drinking days versus placebo.

WTR Healthcare Happenings Podcast Recap: Rewriting the Standard of Care for Severe AUD

United Kingdom

Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, with an initial focus on addiction and mental health. The company is advancing a pipeline of repurposed and novel compounds, including lead programs addressing Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). Headquartered in London, United Kingdom, the company was founded in 2017.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Solvonis Therapeutics (SVNS LN)

SVNS: New Data Sharpens SVN-001's Path to European Expansion

SVN-001 clinical case strengthened. Solvonis has reported two new secondary analyses of the Phase 2 KARE trial of SVN-001, its ketamine-assisted...

Water Tower Research

SVNS: SVN-015 Clears First NIDA Hurdle; Adds Validation and Optionality to Solvonis' CNS Pipeline

That stage should cover confirmatory studies of how SVN-015 binds to and acts on the dopamine transporter, a closer look at its activity at the 5...

Water Tower Research

SVNS: Pursuing Acute Intervention Rather Than Chronic Treatment of High-Burden CNS Conditions

Solvonis is developing acute, durable interventions for high-burden central nervous system (CNS) disorders rather than chronic maintenance therapies.

Water Tower Research

Solvonis' Approach to Resetting the Addicted Brain

The first advancing ketamine as a major alternative to existing addiction treatments and the second developing legal MDMA substitutes, currently in...

Water Tower Research

WTR Healthcare Happenings Podcast Recap: Rewriting the Standard of Care for Severe AUD

Solvonis has shifted from pursuing an earlier-stage out-licensing strategy for its lead development asset for alcohol use disorder (AUD) toward...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)